BioCentury
ARTICLE | Clinical News

Merck KGaA reports Phase I response data for M7824 in HPV-associated cancer

July 13, 2018 7:18 PM UTC

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a Phase I trial of M7824 to treat advanced or metastatic HPV-associated malignancies, including cervical, anal and squamous cell carcinoma of the head and neck (SCCHN).

In the open-label, U.S. trial, 1,200 mg IV M7824 every two weeks led to objective response rates (ORRs) of 35.3% in 17 patients with HPV-associated cancer and 41.7% in 12 patients with proven HPV-positive disease. M7824 also led to signs of tumor burden reduction in 47% of the 17 patients with HPV-associated cancer...